Adam M. Brufsky
Expertise in
20
conditions

Dr. Adam M. Brufsky

Oncology | Hematology Oncology
University Of Pittsburgh Physicians
200 Lothrop St, Muh 4 East, 
Pittsburgh, PA 
 (451.8 mi)
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Expertise in
20
conditions
University Of Pittsburgh Physicians
200 Lothrop St, Muh 4 East, 
Pittsburgh, PA 
 (451.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Adam Brufsky is an Oncologist and a Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Brufsky is highly rated in 20 conditions, according to our data. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy.

His clinical research consists of co-authoring 304 peer reviewed articles and participating in 43 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Specialist in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Upmc Passavant
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Muh 4 East, Pittsburgh, PA 15213
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

37 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Enrollment Status: Recruiting
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
Study Phase: Phase 2
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 04, 2024
Intervention Type: Other
Study Phase: Not Applicable
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: tucatinib, trastuzumab deruxtecan
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: ladiratuzumab vedotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: September 19, 2024
Intervention Type: Procedure, Other
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Procedure, Other, Drug, Biological
Study Drugs: Entinostat, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Procedure, Drug
Study Drugs: carboplatin, paclitaxel, atezolizumab
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2024
Intervention Type: Drug, Procedure
Study Drugs: HKI-272, Capecitabine, Ado-Trastuzumab Emtansine
Study Phase: Phase 2
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib
Enrollment Status: Terminated
Publish Date: February 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Abemaciclib, Non-steroidal AI or steroidal AI or Fulvestrant
Study Phase: Phase 3
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer
Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: November 04, 2022
Intervention Type: Other, Drug
Study Drugs: Onalespib, Paclitaxel
Study Phase: Phase 1
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
Enrollment Status: Terminated
Publish Date: May 17, 2022
Intervention Type: Other
View 34 Less Clinical Trials

304 Total Publications

Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.
Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.
Journal: Future oncology (London, England)
Published: January 27, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. Taofeek K. Owonikoko
Hematology Oncology | Hematology | Oncology
200 Delafield Rd, Suite 3050, 
Pittsburgh, PA 
 (4.8 mi)
412-781-3744
Languages Spoken:
English, German, Spanish, Yoruba
See accepted insurances
Accepting New Patients

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Owonikoko is highly rated in 22 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Liza C. Villaruz
Expertise in
14
conditions
Dr. Liza C. Villaruz
Oncology | Hematology Oncology
Expertise in
14
conditions
Dr. Liza C. Villaruz
Oncology | Hematology Oncology

University Of Pittsburgh Physicians

5230 Centre Ave, 
Pittsburgh, PA 
 (1.4 mi)
412-623-2047
Languages Spoken:
English
See accepted insurances

Liza Villaruz is an Oncologist and a Hematologist Oncology provider in Pittsburgh, Pennsylvania. Dr. Villaruz is highly rated in 14 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

Expertise in
18
conditions
Dr. Radhakrishnan Ramchandren
Hematology Oncology | Oncology | Hematology
Expertise in
18
conditions
Dr. Radhakrishnan Ramchandren
Hematology Oncology | Oncology | Hematology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (1.3 mi)
412-235-1020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Radhakrishnan Ramchandren is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Ramchandren is highly rated in 18 conditions, according to our data. His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ramchandren is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile